Breast cancer (BC) prevention and therapy in the context of life-style risk factors and biological drivers is a major focus of developmental therapeutics in oncology. Obesity, alcohol, chronic estrogen signaling and smoking have distinct BC precipitating and facilitating effects that may act alone or in combination. A spectrum of signaling events including enhanced oxidative stress and changes in estrogen-receptor (ER)-dependent and -independent signaling drive the progression of BC. Breast tumors modulate ERa/ERb ratio, upregulate proliferative pathways driven by ERa and HER2 with a parallel loss and/or
The incidence and progression of breast cancer (BC) is determined and continuously calibrated by genetic, environmental, hormonal and life-style factors that induce and sustain critical changes in cellular signaling networks which in turn impact the efficacy of preventive interventions and response to therapy. [1] [2] [3] [4] According to the latest World Cancer Report (WCR) of International Agency for Research on Cancer (IARC), breast is the most common site of tumor incidence and BC is the most common cause of cancer deaths in women worldwide. 5 Even when statistics for both the sexes are combined, BC is the most prevalent non-skin cancer in the world followed by prostate, colorectal and lung cancers. 5 According to American Cancer Society, 1 in 8 women harbor the life-time risk of developing BC with an estimated 252,710 new invasive BC cases expected to be diagnosed in the year 2017. 6 The prevalence of BC might be determined by multiple factors including timely diagnosis and medical care. According to WCR, BC represents one-fourth of cancers with 5-year prevalence in Middle East and North Africa. 5 In countries transitioning from lower to higher human development index (HDI), the decrease in cervical cancer is offset by increased incidence of BC that could be attributable to both enhanced screening rates and life-style acquired risk-factors like smoking, excessive alcohol consumption, increased obesity, and a combination of them acting collectively to increase the risk for BC (cumulative risk for BC incidence based on HDI: medium HDI, 2.7%; high HDI, 4.9%; very high HDI, 8.4%). 5 In this background, identifying and decreasing the impact of BC risk factors along with developing strategies to enhance the response and tolerance to therapeutic interventions is essential. Integration of novel phytochemicals with therapeutic drugs represents a promising approach to address the strong contemporary need for effective international control and management of BC.
Determinants of BC risk: Considerations for BC prevention and therapy
The genetic causes of BC include aberrations in a number of genes including BRCA1/2, CHK2, ATM, BRIP1, PALB2, CASP8, PTEN and TP53. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] DNA damage resulting from ionizing radiation induces activation of ATM which in turn activates CHK2. 18 CHK2 activation leads to inactivation of Cdc25 phosphatase and further inhibition of CDK2 thereby decreasing proliferation of damaged cells and allowing time for DNA repair. 19 BRCA1/2 mutations occur in 1 in 400 to 1 in 800 people with an estimated 60-85% life-time risk of BC. 15 Furthermore, the loss or dysfunctionality of BRCA1/2 results in genetic damage due to defects in DNA repair by homologous recombination. [15] [16] [17] Missense mutations in the BRIP1/BACH1 gene, which encodes for BRCA1 interacting protein C-terminal helicase 1, predispose to BC in women with a family history of BC. 20, 21 PALB2 is a binding partner of BRCA1 and also an essential protein for the normal function of BRCA2 during repair of DNA double stranded breaks. 22 A recent study has identified that defective PALB2-BRCA1 interaction is associated with increased BC risk. 23 California Teachers Study, a nested case-control study (1, 353 cases and 1,384 controls), identified several single nucleotide polymorphisms (SNPs) in apoptosis initiator CASP8 that were associated with BC risk, while SNP rs2293554 of CASP8 was specifically associated with HER2
1 BC (OR 5 1.98, 95% CI 1.34-2.92). 24 The combined loss of TP53 and PTEN leads to accelerated development of BC that is dependent on eukaryotic elongation factor-2 kinase (eEF2K). 25 In addition to genetic causes, chronic exposure to estrogen in females also serves as a potential risk factor for BC. 26 The estradiol (E2) levels in body are determined by the levels of aromatase. 27 Early menarche and late menopause, which together increase the duration of E2 exposure, are considered to be positively associated with life-time risk for BC incidence. 28 In addition, high serum E2 levels are associated with increased risk of BC in postmenopausal women. 29 E2 treatment enhances the proportion of mammary stem cells and aromatase knockout mice have significantly decreased number of mammary stem cells. 30 The genetic defects in BRCA1 and loss of tumor suppressors PTEN also facilitate an unhindered estrogen induced proliferative signaling by PI3K/AKT pathway due to dysfunctional DNA damage checkpoint, and lack of apoptosis and kinase inhibitory mechanisms. 31, 32 Estrogen receptors a and b (ERa and ERb) mediate the effects of E2 and its metabolites. 33 In normal human mammary gland, ERb is more abundant than ERa.
34 E2 acting on ERa receptors induces transcription of proliferative genes including MAPK, ERK, c-Myc and cyclin D1 that in turn promote breast carcinogenesis. 35, 36 The increased expression of ERa can also lead to estrogen-independent receptor activation and proliferation in BC. 37 The DNA binding domains of ERa and ERb have $95% homology whereas the ligand binding domains have $55% homology. 38, 39 Though the DNA domains of both ERa and ERb have strong homology,
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the ratio of ERa/ERb and consequent changes in the levels of homo and heterodimers of ER receptors determine distinct effects on the transcription of target genes. [38] [39] [40] In a study by Chang EC et al. upon introduction of ERb in to ERa 1
ERb
2 MCF7 BC cells, ERb attenuated growth promoting activity of ERa. 41 In the same study, gene expression analyses revealed that ERb regulates the expression of ERa target genes and reverses the E2 induced upregulation of FOXM1, Cdc25A, E2F1, survivin and BMP7, a regulator of TGFb1 pathway in MCF7 BC cells. 41 In another study conducted to identify genes regulated by ERa and ERb by employing Tetoff regulated ERb expression in ERa 1 ERb 2 T47D BC cells, Williams C et al. identified protein kinase inhibitor beta (PKIB), insulin-like growth factor binding protein 4 (IGFBP4) and IL20 to be upregulated, and TP53-inducible nuclear protein 1 (TP53INP1) and ERBB2/HER2 to be downregulated by ERa. 42 The same study revealed that KCTD11 and glutathione S-transferase theta 2 (GSTT2) to be upregulated, and endothelin 1 and Co-A synthesis enzyme pantothenate kinase 2 (PANK2) to be downregulated by ERb. 42 The effect of ERb is complex with conflicting results reported in BC. The earlier studies indicated that the ERb expression inhibits progression and angiogenesis in vivo xenograft studies and that the expression of ERb is lost during BC progression. 43, 44 A recent study on 187 tumor specimens from BC patients reported that ERb was enriched in BC stem cell population and that knockdown of ERb results in decreased mammosphere formation thereby providing evidence for a bi-faceted and opposing role of ERb in BC. 45 Thus, the complex interplay between ERa and ERb is still an active area of research with multiple factors such as ERa/ERb ratio and the varying impact from signaling cross-talk between specific tumor pathways and processes regulating distinct final outcomes.
The products of E2 metabolism like 2-hydroxy E2 (2-OH-E2), 4-hydroxy E2 (4-OH-E2), 16-hydroxy E2 (16-OH-E2), and oxygen radicals are known to cause DNA damage. 46 ]. The enzyme CYP1B1 is involved in the conversion of E2 to 4-OH-E2. 51 A recent small case-control study (79 cases and 79 controls) examining the single nucleotide polymorphisms (SNPs) in CYP1B1 showed that GG genotype leading to Asn453ser change and consequent lower protein levels of CYP1B1 was associated with 3 times reduced risk of BC in postmenopausal women, thereby indicating the significance of CYP1B1 activity in generating carcinogenic 4-OH-E2. 52, 53 Smoking, regular intake of alcohol, obesity and high-fat diet are associated with increased risk for BC. According to results from American Cancer Society's Cancer Prevention Study II (CPS-II) Nutrition Cohort involving 73,388 women, BC incidence was higher in current (HR 5 1.24, 95% CI 5 1.07-1.42) and former smokers (HR 51.13, 95% CI 5 1.06-1.21), with a stronger association in women exposed to smoking before birth [HR 5 1.21, 95% CI 5 1.14-1.28]. 54 The BC is responsible for 42% of cancer related deaths in women who consume alcohol. 5 Ethanol decreases the levels of protective BRCA1 and increases the levels of ERa in mice breast tumors. 55, 56 A study on alcohol in ER 1 MCF7 BC cells revealed a positive effect on proliferation and attenuated response to tamoxifen therapy which was mediated by an upregulation of BRAF, a clinical marker of poor response to endocrine therapy in BC. 57, 58 Alcohol intake also raises plasma IGF-II, may enhance susceptibility to mammary carcinogenesis and increase invasiveness of BC cells. [58] [59] [60] [61] Obesity represents a chronic proinflammatory condition. 62 Postmenopausal obese women have 20% higher risk for the incidence of BC compared to nonobese counterparts. 63 BC patients with a BMI ! 30 kg/m 2 have 46% more risk of developing metastases following 10 years and harbor a 38% increased risk of BC-related mortality. 64 The BC risk tends to run down to 2-3 generations in the off-springs of rats exposed to synthetic E2 and/or high fat diet which strongly indicates the need for further studies in assessing the carryover genetic risks in families of obese populations previously exposed to diethylstilbestrol (DES). 65 Obesity associated circulating factors induce over activation of IGF1R pathway and increased oxidative stress which together lead to activation of MAPK, PIP3 and mTOR pathways. 66 Obesity leads to higher levels of leptin which promotes BC progression through JAK/ STAT3 and estrogen pathways. 67 The adipose derived stromal cells (ADSCs) harbor leptin receptors and mediate estrogenic effects in response to paracrine and/or autocrine stimulation by leptin. [68] [69] [70] The aromatase, which is involved in E2 synthesis, is mainly expressed in adipose tissue. 71 The estrogen precursor d-4-androstenedione is converted into E2 by the enzymatic action of aromatase in ADSCs. 72 Interestingly, many breast tumors also express leptin receptors which are positively associated with BC proliferation. 73 Leptin induces TGFb1 expression, decreases the epithelial marker Ecadherin and increases EMT marker SNAI2 in BC cells. 74 In addition, leptin increases the CD44
1

/CD24
2 stem cell population in BC cells. 75 HER2 and leptin have mutual inductive effects and leptin decreases the sensitivity to anti-HER2 interventions in HER2
1 BC. [76] [77] [78] Along with obesity, high intake of fat also stands out as a potential risk factor for BC. In a large prospective cohort study (n 5 337327) with 10062 BC patients, after a span of 11.5 years, a high intake of total fat and high saturated fat was shown to be associated with ER 79 Thus, E2 exposure, regular high alcohol consumption and consistent presence of obesity represent a platform where anti-inflammatory, antidiabetic and antiproliferative natural phytochemicals can be beneficial for significant reduction of lifestyle induced risk for BC (Fig. 1 ).
Natural phytochemicals: Impact on prevention and inhibition of BC Natural phytochemicals from various dietary sources have been widely tested in BC. 80, 81 Flavonoids enriched in citrus fruits have been a strong focus of BC research. 82 Citrus fruits are a source of many anti-inflammatory, antioxidant and anticancer compounds that exert regulatory effect on multiple cancer processes and associated signaling pathways. 83 In a study focused on the protective effects of citrus juice in DMBA generated BC employing two models of low-fat and high-fat fed diet, high-fat-fed mice had more tumors than low-fat-fed mice and mice fed with orange juice displayed lower tumor burden as compared to controls in both the groups. 84 Analyses of six case-control studies using fixed effect meta-analysis also revealed that high intake of citrus fruits was associated with a 10% reduction in the risk for BC [summary OR 5 0.90; 95% CI, 0.85-0.96; p < 0.001]. 85 Citrus peels are a rich source of bio-active flavonoids that have strong anticancer effects. Hesperetin, a citrus flavonoid, inhibits aromatase and causes G1 cell cycle arrest in ER 1 MCF7 BC cells. 86 Hesperetin also inhibits the proliferation of triple-negative MDA-MB-231 BC cells by downregulating glucose transporter GLUT1 and decreasing glucose uptake. 87 In a syngeneic BC study conducted using immunecompetent, ovariectamized and high-fat fed C57BL/6 mice, a molecular background similar to postmenopausal obese women, citrus flavonoid naringenin specifically accumulated in adipose and mammary tissues, decreased tumor burden, adipose tissue mass and adipose tissue inflammation. 88 Naringenin-treated tumors had increase in pAMPK and decrease in cyclin D1. 88 Naringenin is also known to inhibit PKC activation and reduce the secretion of TGFb1 in 4T1 BC cells in vitro, and decrease pulmonary metastases of 4T1 tumors in vivo. 89 Citrus flavonoid nobiletin inhibits angiogenesis in ER 1 BC cells which is associated with downregulation of Src, FAK, STAT3 and paxillin, a common downstream target of both FAK and STAT3. 90 In another study, nobiletin caused threefold inhibition of the survival of triple-negative MDA- Figure 1 . Schematic diagram representing the effect of obesity, chronic estrogen and alcoholic signaling on breast cancer (BC) risk: The obesity, alcohol and estrogen induced upregulation of cellular proliferative, antiapoptotic and metastatic pathways represent a significant risk for BC. In addition, the oxidative and genotoxic stress induced by estrogen signaling along with alcohol-induced downregulation of BRCA1 and increase in ERa can have multiple effects based on the type of BC and the age of patient. This molecular milieu induced by BC risk factors provides a rational platform for assessing the mono-and combinatorial effects and mechanisms of natural phytochemicals that display strong antiproliferative, anti-inflammatory and antidiabetic and/antiobesity properties for effective prevention and therapy of BC.
[Color figure can be viewed at wileyonlinelibrary.com]
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MB-468 BC cells, as compared to ER
1 PR 1 MCF7 and ER 2 PR 2 HER2 1 SK-BR-3 cells, which was associated with G0/ G1 cell cycle arrest and apoptosis through downregulation of antiapoptotic BCL-XL. 91 The flavonoid resveratrol is enriched in grapes and is known to inhibit BC proliferation by inhibiting AKT and activating caspase 9. 92 The lower concentrations of resveratrol (1-40 mM) upregulate the tumor suppressor TP53 and further higher concentrations (60-100 mM) strongly downregulate the expression of ERa. 93 In normal MCF10A cells, resveratrol and synthetic analogs of its methoxystilbene (MS) metabolites, tri, tetra and penta MSs decrease the activation of aryl hydrocarbon receptor (AhR) along with reducing the expression of CYP19, CYP1A1 and CYP1B1, which are involved in estrogen synthesis and metabolism. 94 The indole-3-carbinol (I3C), a product generated by the breakdown of cruciferous vegetable compound glucosinolate glucobrassicin, upregulates BRCA1/2 levels, decreases insulin-like growth factor-1 receptor (IGF1R) and insulin receptor substrate-1 (IRS1) in ERa 1 MCF7 BC cells. 95 The expression of GATA3 is positively associated with ERa levels in BC specimens. 96 The I3C downregulates the levels of ERa protein by enhancing its proteosomal degradation in an AhR-dependent mechanism, a process that leads to further downregulation of GATA3 and decrease in the GATA3-mediated ERa transcription in BC. 97 The active metabolite of I3C, 3,3 0 -diindolylmethane (DIM) causes upregulation of miR-21 and consequent decrease in Cdc25A degradation. 98 Interestingly, DIM caused G1/S phase arrest in ER 1 MCF7 cells by downregulating Cdc25A, CDK2, 4 and 6 along with inducing G2/ M phase arrest in triple-negative MDA-MB-468 BC cells by decreasing Cdc25A, CDK2 and CDK4, without affecting CDK6, one of the G1/S transition regulators. 98 Both I3C and DIM repress the ERa transcription. 99 In addition, DIM has been shown to downregulate critical proteins such as hypoxiainducible factor 1, survivin and HER2 along with upregulating interferon gamma (IFNg) in BC. 100 
Molecular anticancer and antimetastatic mechanisms of natural phytochemicals
Curcubitacins are triterpenoid steroidal compounds naturally present in curcubitaceae family of vegetables such as cucumbers, pumpkins and gourds. 101 Curcubitacin B inhibits ITGA6 and ITGB4, which are overexpressed in breast tumors, and increases the expression of ITGB1 and ITGB3, which are known to cause cell death in BC. 102 In the same study, curcubitacin B also inhibited TGFb1-induced association of HER2 with ITGA6 and reduced the progression of tumors generated in mice using triple-negative MDA-MB-231 and 4T1 cells. 102 The metabolic byproduct of garlic called diallyl trisulfide (DATS) inhibits the progression of BC. DATS treatment leads to downregulation of ERa in ER 1 MCF7 and T47D BC cells. 103 Dachshund homolog 1 (DACH1) normally functions by suppressing SNAI1-mediated EMT and metastases.
104 DACH1 expression is lost in invasive BC. 105 FoxQ1 is highly expressed in triplenegative BC, displays an inverse correlation with the levels of DACH1 and localizes to DACH1 promoter in BC cells. 106 The DATS treatment led to decrease of FoxQ1 protein levels along with inhibiting BC progression and causing a decline in BC stem cell population. 107 The phenethyl isothiocyanate (PEITC) from cruciferous vegetables is another compound that has shown promising anticancer activity via downregulation of HER2, pSTAT3 and Bcl-xL, and upregulation of Bim, Bax and caspase-3 in BC cells. 107, 108 Withaferin-A, an active compound from Withania Somnifera, induces mitotic arrest in tumors of MMTV-neu mice, decreases number and weight of tumors in N-methyl-N-nitrosourea (NMU) induced rat BC model, decreases circulating leptin levels in rat plasma and downregulates transcription factor FoxQ1 and angiogenesis marker CD31 in treated tumors. 109 Curcumin is an active constituent of the herb Curcumin longa and exerts potent anticancer effects in BC. Curcumin acts by downregulating miR-21, VEGFR, NFjB and Wnt/bcatenin signaling and by upregulating PTEN signaling in BC. [110] [111] [112] Anthocyanins are a group of coloring pigments from grapes which display anti-BC effects. Delphidin belongs to the family of Anthocynadins, aglycone forms of anthocyanin group of compounds, and inhibits BC proliferation that is associated with suppression of HER2, ERK1/2, STAT3 and NFjB signaling. [113] [114] [115] Green tea catechol EGCG inhibits ERa, VEGF, FAK and PI3K signaling while exerting antiproliferative effects in BC. 116, 117 Some of the natural phytochemicals display concentrationdependent opposite effects in BC. Quercetin and kaempferol are flavonoids enriched in dietary foods. Both quercetin and kaempferol exert biphasic concentration dependent effects in BC while stimulating BC proliferation at $5-10 mM and inhibiting proliferation at $50-100 mM concentration in vitro cell cultures. [118] [119] [120] Quercetin inhibits Wnt/b-catenin pathway and kaempferol inhibits MAPK pathway in BC cells. [120] [121] [122] Soy isoflavones such as genistein and daidzein exert biphasic effects with lower concentrations stimulating and higher concentrations inhibiting the growth of BC cells. 123 Genistein inhibits ER, HER2 and Notch1 pathways while daidzein inhibits ER and HER2 pathways at BC inhibitory concentrations >10 mM in vitro cell culture models. 123, 124 Current BC therapeutic strategies and challenges
The progression and therapeutic responsiveness of BC is determined by expression of hormone receptors ER and PR, and expression of tyrosine-kinase receptor HER2, which together constitute a common reference point for therapy guidelines. 125 The antiestrogen tamoxifen alone and in combination with radiotherapy is the preferred mode of neoadjuvant endocrine radiotherapy in ER 1 BC patients who are considered candidates for breast conservative therapy (BCT). 126 Aromatase inhibitors (AIs), CDK4 and CDK6 inhibitor palbociclib, selective estrogen receptor downregulator (SERD) fulvestrant and mTOR inhibitor everolimus are used for treating ER 1 metastatic BC. 127 Biphosphonates zoledronic acid or clodronate are used in postmenopausal BC patients who are deemed candidates for systemic therapy. 128 Doxorobucin and cyclophosphamide in combination with docetaxel are also used for neoadjuvant and adjuvant chemotherapy in BC. 129 Addition of HER2 targeting therapies such as HER2 monoclonal antibody trastuzumab is a standard practice during the course of both neoadjuvant and adjuvant therapy in BC patients with HER2 amplification and/ or increased expression. 130 As $75% of BCs are hormone receptor positive, endocrine therapy plays a major role in BC management. 131, 132 Antiestrogens which inhibit the effects of E2 like tamoxifene and raloxifene, SERDs like fulvestrant which decrease ERa levels and aromatase inhibitors like letrazole, anastrazole and exemestane which decrease E2 synthesis together constitute the mainstay of clinically practiced endocrine therapy for BC. In addition, in premenopausal women with hormone receptor positive metastatic BC, ovarian suppression by surgical means or by using luteinizing-hormone releasing hormone (LHRH) agonists is considered. 133, 134 Approximately onethird of the women on 5-year tamoxifen therapy develop recurrence in 15 years. 134 Loss of ERa expression is one of the causes of resistance to tamoxifen and SERDS in $15-20% of BC. In addition, ERa-independent mechanisms play a role in tamoxifen resistance. The expression of ERb in ERa 2 BCs predicts positive outcomes for tamoxifen therapy and is considered a favorable prognostic factor. 135 The lack of PTEN, overexpression and activation of HER2, AKT, MEK, ERK and loss of IGF1R following initial treatment are associated with increased resistance to tamoxifen in BC. 136, 137 The increased levels of ERa downstream effectors such as AP1, SP1, EIF4E, SOX9, LAMP3 and NFjB are also associated with resistance to endocrine therapy in BC. [137] [138] [139] [140] [141] The increased expression and activation of nuclear receptor coactivator 3 (NCOA3, also known as AIB), a co-activator of ERa, is another mechanism of endocrine resistance in BC. 142 The overexpression of ER coactivators such as ER coactivator amplified in breast cancer 1 (AIB1) is an additional ERaindependent mechanism associated with tamoxifen resistance in BC. 142, 143 Doxorubicin induces DNA double-strand breaks along with functioning as an inhibitor of topoisomerase II. 144, 145 Doxorubicin also induces free-radical-mediated damage in targeted cells. 146 The side effects of doxorubicin that limit its dosing considerations include cardiomyopathy, congestive heart failure (CHF) and bone marrow suppression. 147 Along with inducing immunosuppressive effects, cyclophosphamide induces DNA cross-links that activate apoptosis. [148] [149] [150] The toxic effects resulting from the cumulative dosing of cyclophosphamide include hemorrhagic cystititis, alopecia, bone marrow suppression, diarrhea and stomach ache. 149 Docetaxel and paclitaxel are taxanes used in both neoadjuvant and adjuvant therapy of BC. The adverse effects of docetaxel include febrile neutropenia and enhanced treatment-related mortality in patients with liver dysfunction. 151 The mechanisms of resistance to taxanes in BC include overexpression of Pgp, BCL2, BCL-XL, cyclin E, cyclin A and HER2 mediated upregulation of p21.
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Inferences from combination studies involving natural phytochemicals for therapeutic sensitization of BC
The factors that determine risks versus benefits accrued from the combination of phytochemicals include the individual multitargeting mechanistic spectrum and the proportion of unique and converging mechanisms of action of each compound in the combination. Chrysin, a phytochemical from Morinda citrifolia, in combination with apigenin synergistically inhibits BC in vitro and in vivo MDA-MB-231 mice xenografts models of BC. 153 In the same study, chrysin and apigenin decreased extracellular matrix degrader proteins such as MMP9 and MMP2, and EMT markers like fibronectin, slug, vimentin, snail and TWIST to a greater extent in combination than as single agents. 153 The combination of curcumin and berberine synergistically inhibits the survival and proliferation of MCF7 and MDA-MB-231 BC cells. Curcumin and berberine act by strongly upregulating the phosphorylation of JNK and beclin1, and decreasing the levels of antiapoptotic Bcl2 in BC cells. 154 Owing to their multitargeting ability, natural phytochemicals have extensive cross-talk with drugs used in BC therapy. AIs like letrozole are generally used in postmenopausal women while antiestrogens are commonly used in premenopausal women for a period of 5-10 years for preventing BC recurrence. 155 AIs, which decrease the synthesis of E2, have greater efficacy than tamoxifen in decreasing BC recurrence risk. 156 Side effects of tamoxifen include hot flashes, thromboembolism and stroke while aromatase inhibitors cause osteoporosis, joint pains and bone fractures. 157 Luteolin-overexpressed in yellow green plants like celery, green peppers, carrots and olive oildownregulates cyclin E2 and sensitizes tamoxifen-resistant (Tam-R) MCF7 BC cells to tamoxifen treatment. 158 Naringenin exerts anticancer effects in Tam-R MCF7 BC cells by inhibiting ERK and AKT. 159 The bioavailability of tamoxifen is limited by CYP3A4-mediated first pass metabolism in liver and Pgp, BCRP and MRP2-mediated drug efflux in the apical membranes of intestine, liver and kidneys. 160 Quercetin, an inhibitor of CYP3A4 and Pgp, increases the bioavailability of tamoxifen. 161 Though biphosphonates like zolendronic acid or clodronate are administered to prevent AI-induced bone deterioration, AI side effects like esophagitis, ulcers, atrial fibrillation and renal dysfunction are still common in patients. 162 Approximately 15-20% of women on endocrine therapy skip doses and discontinue the treatment due to potential side effects. 163 The citrus flavonoid hesperetin in combination with letrozole accelerates the onset of breast tumor regression while also protecting from letrozole induced bone loss in mice model of postmenopausal BC. 164 Co-administration of luteolin along with letrozole leads to increase in the plasma levels of HDL, thereby causing an overall decrease in letrozole induced rise of LDL/HDL ratio in ovariectomized mice. 165 
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Despite the rise in use of non-anthracycline-based chemotherapy regimens, progress in tyrosine-kinase inhibitors and therapeutic combinations involving taxanes, anthracyclines are prescribed in invasive HER2 2 BC. 166 In an interesting study, olive leaf extract potentiated the effect of anthracycline epirubicin in triple-negative MDA-MB-231 BC cells while antagonizing the effect of epirubicin in ER 1 MCF7 cells, a finding which highlights the need for BC subtype specific combinatorial studies to assess varying responses. 167 The use of higher therapeutic doses of doxorubicin is limited by incidence of cardiomyopathy, a finding more common in geriatric females and in patients with hypertension and a history of previous use of anthracyclines. 168 A recent study revealed that beetroot juice in the concentrations of 0.5-250 mg/ml Hesperetin Inhibits aromatase, and induces G0/G1-phase cell cycle arrest in MCF7 BC cells, and decreases GLUT1 expression in MDA-MB-231 BC cells.
In combination with letrozole, accelerates breast tumor regression and simultaneously protects letrozole-induced bone loss in mice model of postmenopausal breast cancer.
86,87 164
Naringenin Decreases pAMPK and cyclin D1 levels, inhibits activation of PKC, decreases TGFb1 levels, and decreases proliferation of tamoxifen resistant MCF7 cells by inhibiting ERK and AKT.
88,89
Nobiletin Induces G0/G1-phase cell cycle arrest, Downregualtes antiapoptotic Bcl-xL protein, inhibits Src, FAK, STAT3 and paxillin.
90,91
Resveratrol Upregulates TP53, decreases ERa levels and also directly binds to ERa. Inhibits AKT and activates caspase 9. Decreases CYP19, CYP1A1 and CYP1B1.
92-94
Indole 
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Beetroot Juice In combination with doxorubicin, increases doxorubicin-induced apoptosis, and simultaneously protects cardiomyocytes from doxorubicin-induced cardiotoxicity.
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protects from doxorubicin-induced cardiotoxicity in cardiomyocytes and increases doxorubicin induced apoptosis in BC cells. 169 The combination of dietary quercetin and intratumoral injection of doxorubicin led to synergistic reduction in the size of primary tumors and near complete abrogation of lung metastases in 4T1 BC xenografts established in immune-competent BALB/c mice while lesser inhibitory effects were observed in 4T1 xenografts established in immune-deficient nude mice. The combinatorial benefit of quercetin and intratumoral doxorubicin injection was mediated by increase in tumor inhibitory cytokines IL-2 and IFNg, and decrease in immune-inhibitory cytokines IL-4 and IL-10 in both 4T1 tumors and serum of immune-competent BALB/c mice. This study by Du et al. also serves as an example for the need of including immune-competent mice along with nude mice models to study the effect of potential immune-mediated mechanisms triggered by the combination of phytochemicals and therapeutic drugs. 170 Translational opportunities for decreasing primary BC risk and improving quality of life by combinatorial studies
The BC contributes to 48.1% of disability adjusted life years (DALY, a measure of years lost due to ill health, disability or premature mortality) in women worldwide. 5 The results from a case-control study assessing the dose-and formulationdependent risk associated with the use of combined estrogenprogestin oral contraceptive pills (COCP) in 20-49 year women revealed that recent use of COCP within one year was associated with risk for ER 1 BC as compared to never or former COCP users [(OR 5 1.5, 95% CI 5 1.3-1.9)]. 171 As human behavioral habits are challenging to change due to prevalent cultures, this finding on COCP suggests the need to study the effects of natural phytochemicals in combination with COCP to assess noninterference with the efficacy of COCP and a parallel reduction in the markers of BC risk. Alcohol and smoking have a potentiating role on E2 and oxidative stress signaling, a fact which warrants large scale studies with natural phytochemicals to assess the impact on BC incidence and associated markers of BC risk. [54] [55] [56] The alcohol induced folate deficiency and consequent decline in cellular methionine synthesis could lead to reprogramming of gene expression, an area in which detailed studies are warranted to assess the impact on BC-specific gene expression. 57 In addition, global hypomethylation in leukocytes has been shown to be associated with increased risk for BC. 172 Though folate can ameliorate methionine deficiency, the alcohol-induced defects in intestinal folate absorption is a limitation for oral folate supplementation. 173 Further studies on the efficacy of phytochemicals to reverse hypomethylation-induced genetic aberrations are needed. Advanced glycation end-products (AGE) resulting from nonenzymatic glycation are associated with increased risk and progression of BC. 174 Exogenous AGE treatment leads to stimulation of BC cell proliferation, migration and invasion. 175 Many flavonoids like vicenin-2 exert anticancer and antiglycation effects along with potentiating the effect of docetaxel which need to be further explored for studying both BC risk-reduction and combinatorial therapeutic benefits. 176, 177 Metastatic BC is another area where the role of natural phytochemicals and rational combinations needs to be explored. The stage IV BC represents metastatic disease with a dismal 5-year survival rate of 22%. 1 Bone metastases of BC occurs in $70% of BC patients while brain metastasis of BC occurring in 15-20% cases represents a severe and painful condition associated with very poor survival. 178 The CXCR4
increases SRC signaling and enhances the affinity of BC cells to endothelium during bone metastases. 179 Brain metastases are more common in ER
2
, PR 2 and HER2 1 BC. 180 The levels of a-2, 6 sialyltransferase 5 (ST6GALNAC5) determine BC cell affinity to brain endothelial cells, COX-2 increases the permeability of blood-brain barrier vasculature, and HB-EGF enhances the invasiveness of BC cells to promote brain metastases. [181] [182] [183] Many flavonoids are COX-2 inhibitors and decrease EGF signaling. [82] [83] [84] RLIP76, a multifunctional protein associated with drug-and radiation-resistance and metastatic progression, is increased in BC and downregulated by treatment with 2 0 -hydroxyflavanone. 184, 185 Activation of notch signaling is another potent mechanistic factor associated with both metastases and increased risk for tumor recurrence in HER2-driven BC models. 186, 187 Many natural phytochemicals like flavonoids have strong antioxidant, anti-inflammatory and anticancerous properties which makes them great choice for combinatorial chemoprevention and therapy of BC [82] [83] [84] (Table 1 ). The characteristic ERa and ERb binding profiles of phytochemicals are an important factor to be considered for BC interventions. The specific effects of estrogen and its metabolites on ER isoforms need to be carefully considered in developing combinatorial interventions with phytochemicals. Bioidentical hormone therapy [b(HT)] is being considered as an alternative to conventional hormone therapy (HT). 188 In a recent study, Perkins et al. revealed that estrone (E1) has low affinity for ERb and ethinyl estradiol (EE) has higher affinity for ERa. 189 In the same study, estriol (E3) was found not to antagonize the activity of estradiol (E2) as claimed by many proponents of b(HT). 188, 189 Also, both bioidentical estradiol (bE2) and estriol (bE3) used in [b(HT)] were found to be full estrogen agonists. 189 The grape flavonoid resveratrol directly binds to ERa with a more stable antagonistic conformation compared to low energy agonistic conformation. 190 Apigenin exerts anticancer effects through ERb transactivation dependent mechanism in ERa 2 MDA-MB-231BC cells. 191 Ligand binding studies revealed that genistein, daidzen and equol bind with high affinity to ERb as compared to ERa. 192 Some phytochemicals also directly bind and affect the function of other critical tumor proteins in BC. PEITC covalently modifies the N-terminal proline residue of macrophage migration inhibitory factor (MIF) and decreases its tautomerase activity that is essential for its tumor promoting effects. 193 Withaferin-A
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directly binds to Cys 303 of b tubulin, disrupts mitotic spindle and inhibits proliferation of BC cells. 194, 195 Well-designed and carefully executed studies on the combinations of flavonoids with other phytochemicals and/or chemotherapy drugs are needed to further characterize the potential benefits in BC. The major factors to be considered in such much needed studies include the following: (i) Studying the effects of combinations of promising flavonoids in a background of obesity, E2 and genetic risk factors in animal models to assess the impact on associated signaling cascades and BC risk reduction. Obesity potentiates both E2 signaling and enhances the risk for recurrence of BC in postmenopausal women. Thus, characterization of the beneficial effects of combinations of flavonoids with or without chemotherapy drugs will establish much needed translational evidence for effective primary and tertiary prevention of BC in this highrisk population. 
Conclusions
The recent studies on genetic, environmental, hormonal and life-style risk factors have elucidated a multiplanar cross-talk between the molecular determinants of BC incidence and progression. The current interventional options for BC are highly focused on single target approaches or a combination of them. The adherence to hormonal therapy in postmenopausal women with ER 1 BC is often lacking. In addition, the conventional drug development efforts to circumvent therapy-induced side effects are commonly focused on studying combinations with other class of therapeutic drugs or single-target agents. Natural phytochemicals modulate the chronic inflammatory impact of BC risk factors like obesity, increase the efficacy of chemotherapy drugs on BC cells and influence ER isoform levels along with having larger regulatory effect on BC proliferation and metastases signaling networks. Hence, novel combinations of phytochemicals with developmental agents and/or chemotherapy drugs will accelerate the realization of effective solutions to expand and strengthen the interventional strategies at multiple levels of BC prevention and therapy.
